BPC-157 vs P21 (Cerebrolysin Analog)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

BPC-157P21 (Cerebrolysin Analog)
CategoryPeptidesPeptides
Standard DoseResearch indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
TimingAdminister on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.Morning dosing preferred for cognitive effects.
Cycle DurationTypical cycles range from 4-12 weeks depending on the injury being addressed.4-8 week cycles with 4-week rest periods.
Evidence Levelanimal_plus_anecdotalanimal_plus_anecdotal
A

BPC-157

Peptides

Mechanism

BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.

Timing

Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.

Cycle Duration

Typical cycles range from 4-12 weeks depending on the injury being addressed.

Side Effects

  • Mild nausea (rare)
  • Dizziness (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer or history of cancer (theoretical concern with angiogenesis promotion)
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuPentadeca Arginate (PDA)

Mechanism

P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.

Standard Dosing

Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.

Timing

Morning dosing preferred for cognitive effects.

Cycle Duration

4-8 week cycles with 4-week rest periods.

Side Effects

  • Mild headache
  • Nasal irritation (intranasal)
  • Increased appetite (CNTF pathway modulation)
  • Vivid dreams

Contraindications

  • Pregnancy and breastfeeding
  • Active seizure disorders

Best Stacking Partners

SemaxSelankDihexa

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →